Search results
Biogen to buy San Francisco startup developing a drug for kidney disease for $1.2B - Boston Business...
The Business Journals· 4 days agoBiogen Inc. is shelling out $1.15 billion upfront to buy a South San Francisco immunology company....
Arbutus, Novavax See Activist Investor Action
Barrons.com· 1 day agoMcElhaugh’s statement that Arbutus doesn’t anticipate further at-the-market share issuances this year due to its substantial...
Arizona researcher publishes study on COVID-19 vaccine and tinnitus
ABC 15 Phoenix· 1 day agoA newly published scientific study about the COVID-19 vaccine found people with certain preexisting medical conditions were more likely to report ringing in the ears after getting immunized.
Biotech stocks are rising alongside bird flu fears
Semafor via Yahoo Finance· 3 days agoVaccine makers, including Moderna, BioNTech, and CureVac, all saw double-digit stock increases, as investors bet they could cash in on a public health...
The Zacks Analyst Blog Highlights Stocks recently featured in the blog include: Novo Nordisk, Eli...
Zacks via Yahoo Finance· 6 days agoAfter all, Moderna was not the behemoth it is today. Until 2020-end, the company lacked a marketed...
Vaccine makers receive stock boost after third human bird flu case in US
Newsweek· 3 days agoShares in some companies that produce vaccines have seen stock boosts following a small number of...
Why Novavax (NVAX) Stock Price Appreciated 14% on Monday
Zacks via Yahoo Finance· 5 days agoNovavax (NVAX) surges after one of its top shareholders drops a proxy campaign against the company....
Cleburne rebounds from four runs down to end RedHawks' win streak
The Fargo Forum· 1 day agoCleburne rallied from four runs down to defeat Fargo-Moorhead 9-5 on Friday at La Moderna Field. The...
3 Cathie Wood Stocks to Buy Now: May 2024
InvestorPlace· 5 days agoCathie Wood’s ARK Invest funds were unstoppable in 2020 as investors piled into disruptive innovation stocks during the low-rate lockdown environment. After peaking in early 2021, the ARK funds ...
Here's Why Merck (MRK) Stock Has Outperformed Industry YTD
Zacks· 6 days agoFree Report) boasts more than six blockbuster drugs in its portfolio, with PD-L1 inhibitor Keytruda approved for several types of cancer and alone accounting for more than 45% of the company ...